Tg Therapeutics (TGTX) Income from Continuing Operations: 2016-2025
Historic Income from Continuing Operations for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $390.9 million.
- Tg Therapeutics' Income from Continuing Operations rose 10006.23% to $390.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.5 million, marking a year-over-year increase of 3212.81%. This contributed to the annual value of $23.4 million for FY2024, which is 84.52% up from last year.
- Tg Therapeutics' Income from Continuing Operations amounted to $390.9 million in Q3 2025, which was up 1,286.84% from $28.2 million recorded in Q2 2025.
- Tg Therapeutics' Income from Continuing Operations' 5-year high stood at $390.9 million during Q3 2025, with a 5-year trough of -$94.0 million in Q4 2021.
- For the 3-year period, Tg Therapeutics' Income from Continuing Operations averaged around $41.8 million, with its median value being $5.1 million (2025).
- In the last 5 years, Tg Therapeutics' Income from Continuing Operations tumbled by 96.60% in 2024 and then spiked by 10,006.23% in 2025.
- Over the past 5 years, Tg Therapeutics' Income from Continuing Operations (Quarterly) stood at -$94.0 million in 2021, then rose by 14.49% to -$80.4 million in 2022, then soared by 82.07% to -$14.4 million in 2023, then soared by 261.92% to $23.3 million in 2024, then spiked by 10,006.23% to $390.9 million in 2025.
- Its Income from Continuing Operations stands at $390.9 million for Q3 2025, versus $28.2 million for Q2 2025 and $5.1 million for Q1 2025.